	US 12,134,657 B2
	Therapeutic factor XII antibody
Michael Wallisch, Portland, OR (US); Andras Gruber, Portland, OR (US); Erik I. Tucker, Portland, OR (US); and Christina U. Lorentz, Portland, OR (US)
Assigned to Oregon Health & Science University, Portland, OR (US); and Aronora, Inc., Portland, OR (US)
Appl. No. 17/297,967
Filed by Oregon Health & Science University, Portland, OR (US); and Aronora, Inc., Portland, OR (US)
PCT Filed Nov. 27, 2019, PCT No. PCT/US2019/063729 § 371(c)(1), (2) Date May 27, 2021, PCT Pub. No. WO2020/113084, PCT Pub. Date Jun. 4, 2020.
Claims priority of provisional application 62/772,235, filed on Nov. 28, 2018.
Prior Publication US 2022/0089776 A1, Mar. 24, 2022
Int. Cl. C07K 16/36 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); A61P 7/02 (2006.01)

CPC C07K 16/36 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 49/0002 (2013.01); A61P 7/02 (2018.01); A61K 39/00 (2013.01); A61K 2039/545 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01)]

21 Claims

1. A monoclonal antibody that binds blood protein factor XII (FXII), or an antigen-binding fragment thereof, comprising a variable heavy (VH) domain and a variable light (VL) domain, wherein:

the amino acid sequence of the VH domain comprises SEQ ID NO: 8; and

the amino acid sequence of the VL domain comprises SEQ ID NO: 10.